Clinical trials
Hypertension trials in Vietnam
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 7 |
| A.Menarini Asia-Pacific Holdings Pte Ltd | 1 |
| Boehringer Ingelheim | 1 |
| Chinese University of Hong Kong | 1 |
| Hospital Israelita Albert Einstein | 1 |
| Institute of Population, Health and Development, Vietnam | 1 |
| Ministry of Health, Vietnam | 1 |
| Pham Ngoc Thach University of Medicine | 1 |
| Phenikaa University | 1 |
| Sanofi | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 21 |
| Diabetes Mellitus, Type 2 | 5 |
| Cardiovascular Diseases | 3 |
| Diabetes Mellitus | 2 |
| Renal Insufficiency, Chronic | 2 |
| Disease | 1 |
| Pre-Eclampsia | 1 |
| Sleep Initiation and Maintenance Disorders | 1 |
Trials
Showing 51 to 21 of 21. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.